Cervical cancer cell supernatants induce a phenotypic switch from U937-derived macrophage-activated M1 state into M2-like suppressor phenotype with change in toll-like receptor profile

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Sánchez Reyes, Karina ^a,b   Bravo Cuellar, Alejandro ^a,b   Hernández Flores, Georgina ^a   Lerma Díaz, José Manuel ^a,b   Jave Suárez, Luis Felipe ^a   Gómez Lomelí, Paulina ^a,b   De Celis, Ruth ^a   Aguilar Lemarroy, Adriana ^a   Domínguez Rodríguez, Jorge Ramiro ^a,b   Ortiz Lazareno, Pablo Cesar ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; NITRIC OXIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; AUTACOID; CD163 ANTIGEN; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; TOLL LIKE RECEPTOR 9;

ARTICLE; CERVICAL CANCER CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MACROPHAGE; MACROPHAGE ACTIVATION; PHENOTYPE; PROTEIN EXPRESSION; SUPERNATANT; U937 CELL LINE; BIOSYNTHESIS; CELL FRACTIONATION; DRUG EFFECTS; FEMALE; METABOLISM; PATHOLOGY; SECRETION (PROCESS); TUMOR CELL LINE; UPREGULATION; UTERINE CERVIX TUMOR;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL LINE, TUMOR; CYTOKINES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; NITRIC OXIDE; PHENOTYPE; RECEPTORS, CELL SURFACE; SUBCELLULAR FRACTIONS; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9; TOLL-LIKE RECEPTORS; U937 CELLS; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 84911935667     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/683068     Document Type: Article

References (43)

1. Woodman C. B. J., Collins S. I., Young L. S., The natural history of cervical HPV infection: unresolved issues. Nature Reviews Cancer 2007 7 1 11 22 10.1038/nrc2050 2-s2.0-33845905779
2. Frazer I. H., Prevention of cervical cancer through papillomavirus vaccination. Nature Reviews Immunology 2004 4 1 46 54 10.1038/nri1260 2-s2.0-0345827680
3. Tindle R. W., Immune evasion in human papillomavirus-associated cervical cancer. Nature Reviews Cancer 2002 2 1 59 65 10.1038/nrc700 2-s2.0-0036364468
4. Burd E. M., Human papillomavirus and cervical cancer. Clinical Microbiology Reviews 2003 16 1 1 17 10.1128/CMR.16.1.1-17.2003 2-s2.0-0037243946
5. Woodworth C. D., HPV innate immunity. Frontiers in Bioscience 2002 7 d2058 d2071 10.2741/woodworth 2-s2.0-0036778165
6. Mosser D. M., Edwards J. P., Exploring the full spectrum of macrophage activation. Nature Reviews Immunology 2008 8 12 958 969 10.1038/nri2448 2-s2.0-56749174940
7. Hao N. B., Lu M. H., Fan Y. H., Cao Y. L., Zhang Z. R., Yang S. M., Macrophages in tumor microenvironments and the progression of tumors. Clinical and Developmental Immunology 2012 2012 11 948098 10.1155/2012/948098
8. Biswas S. K., Mantovani A., Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunology 2010 11 10 889 896 10.1038/ni.1937 2-s2.0-77956976681
9. Solinas G., Germano G., Mantovani A., Allavena P., Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. Journal of Leukocyte Biology 2009 86 5 1065 1073 10.1189/jlb.0609385 2-s2.0-70350728931
10. Iwasaki A., Medzhitov R., Toll-like receptor control of the adaptive immune responses. Nature Immunology 2004 5 10 987 995 10.1038/ni1112 2-s2.0-5444262511
11. Xu J., Yang Y., Sun J., Ding Y., Su L., Shao C., Jiang B., Expression of Toll-like receptors and their association with cytokine responses in peripheral blood mononuclear cells of children with acute rotavirus diarrhoea. Clinical and Experimental Immunology 2006 144 3 376 381 10.1111/j.1365-2249.2006.03079.x 2-s2.0-33744473038
12. Decarlo C. A., Rosa B., Jackson R., Niccoli S., Escott N. G., Zehbe I., Toll-like receptor transcriptome in the HPV-positive cervical cancer microenvironment. Clinical and Developmental Immunology 2012 2012 9 785825 10.1155/2012/785825
13. Daud I. I., Scott M. E., Ma Y., Shiboski S., Farhat S., Moscicki A.-B., Association between toll-like receptor expression and human papillomavirus type 16 persistence. International Journal of Cancer 2011 128 4 879 886 10.1002/ijc.25400 2-s2.0-78650542756
14. Hammes L. S., Tekmal R. R., Naud P., Edelweiss M. I., Kirma N., Valente P. T., Syrjänen K. J., Cunha-Filho J. S., Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression-clinicopathological correlation. Gynecologic Oncology 2007 105 1 157 165 10.1016/j.ygyno.2006.11.023 2-s2.0-33947330625
15. Ong S.-M., Tan Y.-C., Beretta O., Jiang D., Yeap W.-H., Tai J. J. Y., Wong W.-C., Yang H., Schwarz H., Lim K.-H., Koh P.-K., Ling K.-L., Wong S.-C., Macrophages in human colorectal cancer are pro-inflammatory and prime T cells towards an anti-tumour type-1 inflammatory response. European Journal of Immunology 2012 42 1 89 100 10.1002/eji.201141825 2-s2.0-84855219213
16. Mantovani A., Schioppa T., Porta C., Allavena P., Sica A., Role of tumor-associated macrophages in tumor progression and invasion. Cancer and Metastasis Reviews 2006 25 3 315 322 10.1007/s10555-006-9001-7 2-s2.0-33845524204
17. + Th1 cells. Journal of Immunology 2011 187 3 1157 1165 10.4049/jimmunol.1100889 2-s2.0-80051627660
18. Daigneault M., Preston J. A., Marriott H. M., Whyte M. K. B., Dockrell D. H., The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS ONE 2010 5 1 e8668 10.1371/journal.pone.0008668
19. Dreskin S. C., Thomas G. W., Dale S. N., Heasley L. E., Isoforms of jun kinase are differentially expressed and activated in human monocyte/macrophage (THP-1) cells1. The Journal of Immunology 2001 166 9 5646 5653 10.4049/jimmunol.166.9.5646 2-s2.0-0035339885
20. Hintz K. A., Rassias A. J., Wardwell K., Moss M. L., Morganelli P. M., Pioli P. A., Givan A. L., Wallace P. K., Yeager M. P., Guyre P. M., Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163. Journal of Leukocyte Biology 2002 72 4 711 717 2-s2.0-0036826676
21. Buechler C., Ritter M., Orsó E., Langmann T., Klucken J., Schmitz G., Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. Journal of Leukocyte Biology 2000 67 1 97 103 2-s2.0-0001930725
22. Chen N., Qi C., Chen Y., Ding W., He Q.-Y.,. Colon cancer cell supernatant polarized THP-1 macrophages to a M2-like phenotype
23. Porcheray F., Viaud S., Rimaniol A.-C., Léone C., Samah B., Dereuddre-Bosquet N., Dormont D., Gras G., Macrophage activation switching: an asset for the resolution of inflammation. Clinical and Experimental Immunology 2005 142 3 481 489 10.1111/j.1365-2249.2005.02934.x 2-s2.0-28344449833
24. Stout R. D., Watkins S. K., Suttles J., Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages. Journal of Leukocyte Biology 2009 86 5 1105 1109 10.1189/jlb.0209073 2-s2.0-70350529527
25. Bächli E. B., Schaer D. J., Walter R. B., Fehr J., Schoedon G., Functional expression of the CD163 scavenger receptor on acute myeloid leukemia cells of monocytic lineage. Journal of Leukocyte Biology 2006 79 2 312 318 10.1189/jlb.0605309 2-s2.0-33646464894
26. Nanpeng C., Caiwa Q., Ying C., Wen D., Qingyu H., Colon cancer cell supernatant polarized THP-1 macrophages to a M2 like phenotype. Methods 2011 1 1
27. Linde N., Lederle W., Depner S., Van Rooijen N., Gutschalk C. M., Mueller M. M., Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages. The Journal of Pathology 2012 227 1 17 28 10.1002/path.3989 2-s2.0-84859643154
28. Hess S., Smola H., de Silva U. S., Hadaschik D., Kube D., Baldus S. E., Flucke U., Pfister H., Loss of IL-6 receptor expression in cervical carcinoma cells inhibits autocrine IL-6 stimulation: abrogation of constitutive monocyte chemoattractant protein-1 production. The Journal of Immunology 2000 165 4 1939 1948 10.4049/jimmunol.165.4.1939 2-s2.0-0034663922
29. Bauknecht T., Randelzhofer B., Schmitt B., Ban Z., Hernando J.-J., Bauknecht T., Response to IL-6 of HPV-18 cervical carcinoma cell lines. Virology 1999 258 2 344 354 10.1006/viro.1999.9722 2-s2.0-0033526507
30. Wei L.-H., Kuo M.-L., Chen C.-A., Chou C.-H., Cheng W.-F., Chang M.-C., Su J.-L., Hsieh C.-Y., The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene 2001 20 41 5799 5809 10.1038/sj.onc.1204733 2-s2.0-0035855625
31. Kapp U., Yeh W.-C., Patterson B., Elia A. J., Kägi D., Ho A., Hessel A., Tipsword M., Williams A., Mirtsos C., Itie A., Moyle M., Mak T. W., Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. The Journal of Experimental Medicine 1999 189 12 1939 1946 10.1084/jem.189.12.1939 2-s2.0-0033591689
32. Fujisawa T., Joshi B., Nakajima A., Puri R. K., A novel role of interleukin-13 receptor 2 in pancreatic cancer invasion and metastasis. Cancer Research 2009 69 22 8678 8685 10.1158/0008-5472.CAN-09-2100 2-s2.0-72249115096
33. Ritter M., Buechler C., Langmann T., Orso E., Klucken J., Schmitz G., The scavenger receptor CD163: regulation, promoter structure and genomic organization. Pathobiology 1999 67 5-6 257 261 2-s2.0-0342905414
34. Tilg H., Dinarello C. A., Mier J. W., IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunology Today 1997 18 9 428 432 10.1016/S0167-5699(97)01103-1 2-s2.0-0030823183
35. Rangel-Corona R., Corona-Ortega T., Soto-Cruz I., López-Labra A., Pablo-Arcos T., Torres-Guarneros C. F., Weiss-Steider B., Evidence that cervical cancer cells secrete IL-2, which becomes an autocrine growth factor. Cytokine 2010 50 3 273 277 10.1016/j.cyto.2010.02.013 2-s2.0-77952542830
36. Suminami Y., Kashii Y., Law J. C., Lin W.-C., Stanson J., Reichert T. E., Rabinowich H., Whiteside T. L., Molecular analysis of the IL-2 receptor β chain gene expressed in human tumor cells. Oncogene 1998 16 10 1309 1317 10.1038/sj.onc.1201640 2-s2.0-0032510273
37. Mindiola R., Callejas D., Núñez-Troconis J., Araujo M., Delgado M., Mosquera J., Increased number of IL-2, IL-2 receptor and IL-10 positive cells in premalignant lesions of the cervix. Investigacion Clinica 2008 49 4 533 545 2-s2.0-61549122661
38. Reichert T. E., Nagashima S., Kashii Y., Stanson J., Gao G., Dou Q. P., Whiteside T. L., Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression. Oncogene 2000 19 4 514 525 10.1038/sj.onc.1203391 2-s2.0-0034719334
39. Bogdan C., Nitric oxide and the immune response. Nature Immunology 2001 2 10 907 916 10.1038/ni1001-907 2-s2.0-0034769118
40. Bauer P. M., Buga G. M., Fukuto J. M., Pegg A. E., Ignarro L. J., Nitric oxide inhibits ornithine decarboxylase via s-nitrosylation of cysteine 360 in the active site of the enzyme. The Journal of Biological Chemistry 2001 276 37 34458 34464 10.1074/jbc.M105219200 2-s2.0-0035860704
41. Pervin S., Singh R., Chaudhuri G., Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): potential role of cyclin D1. Proceedings of the National Academy of Sciences of the United States of America 2001 98 6 3583 3588 10.1073/pnas.041603998 2-s2.0-0035853035
42. Banerjee S., Halder K., Bose A., Bhattacharya P., Gupta G., Karmahapatra S., Das S., Chaudhuri S., Majumdar S. B., TLR signaling-mediated differential histone modification at IL-10 and IL-12 promoter region leads to functional impairments in tumor-associated macrophages. Carcinogenesis 2011 32 12 1789 1797 2-s2.0-81855173525 10.1093/carcin/bgr208
43. Ridnour L. A., Cheng R. Y. S., Switzer C. H., Heinecke J. L., Ambs S., Glynn S., Young H. A., Trinchieri G., Wink D. A., Molecular pathways: toll-like receptors in the tumor microenvironment-poor prognosis or new therapeutic opportunity. Clinical Cancer Research 2013 19 6 1340 1346 10.1158/1078-0432.CCR-12-0408 2-s2.0-84875189381